Protocols & References
Mechanism-level overviews of the compounds researchers ask about most — sourced from published preclinical literature, with explicit limitations noted throughout. Nothing here is a health, dosing or treatment claim; it's a summary of what the current research does and doesn't show.
BPC-157: Mechanisms of Action and Research Applications
A deep-dive into Body Protection Compound-157, its gastroprotective origins, and its expanding role in musculoskeletal and neurological recovery research.
IGF-1 LR3: Extended Half-Life Analog in Tissue Growth Research
How a 13-amino-acid B-domain extension and single point mutation transform native IGF-1 into a long-acting research tool for studying anabolic signaling and satellite cell activity.
TB-500: The Thymosin Beta-4 Actin-Binding Fragment in Repair Research
How a 43-amino-acid synthetic fragment of Thymosin Beta-4 became a widely studied tool compound for actin dynamics, cell migration, and tissue-repair research.
BPC-157 vs TB-500 — What the Preclinical Evidence Actually Compares
BPC-157 vs TB-500 is routinely framed as a choice between interchangeable compounds, or as a natural pairing. The published literature supports neither reading — and in July 2026 they were finally tested head to head.